SAN903 / Saniona - LARVOL DELTA

BioStock: Saniona ready for phase I with SAN903 (Market Screener) - "Saniona has finalised preclinical studies with its anti inflammatory and anti-fibrotic drug candidate SAN903. According to the company, compelling data indicates that the candidate has the potential to become a first-line treatment in patients suffering from inflammatory bowel disease."

Clinical • Immunology • Inflammatory Bowel Disease

"BioStock: Saniona redo för fas I med SAN903 https://t.co/f40nhLyNqS" (@CisionNews)

"BioStock: Saniona ready for phase I with SAN903 https://t.co/HUyEPsm4yp" (@CisionNews)

Saniona’s anti-inflammatory and anti-fibrotic candidate SAN903 is ready for clinical studies (Yahoo Finance) - "Saniona...announced that SAN903 is ready to start the regulatory process for entering Phase 1 clinical trials either by Saniona alone or together with a partner following successful completion of preclinical development. 'Preclinical data for SAN903 are very compelling and we believe it has potential to become first-line treatment in patients suffering from inflammatory bowel disease, IBD, where it could be the first maintenance drug with independent actions on both acute inflammation and chronic fibrotic complications. Other potential indications include fibrotic disorders such as chronic kidney disease, CKD, and the fatal lung disease idiopathic pulmonary fibrosis, IPF. There is a significant unmet medical need and commercial opportunities in inflammatory bowel disease and rare fibrotic disorders.'"

New P1 trial • Preclinical • Idiopathic Pulmonary Fibrosis • Immunology • Inflammatory Bowel Disease

Saniona Announces Refocused Strategy on Ion Channel R&D and Restructuring of Board of Directors and Executive Management Team (GlobeNewswire) - "The company will pursue partnerships for its later-stage clinical programs, Tesomet and SAN711, and refocus its resources by prioritizing investment in specific research and development pipeline programs and its core expertise in ion channel drug discovery....SAN903 to be developed internally: Saniona advanced preclinical development of SAN903 over the past two years and continues to expect completion in the first half of 2022. Given the significant organizational changes and transitions, the company now plans to initiate a Phase 1 clinical trial with SAN903 by the end of 2022 or in early 2023. This potential first-in-class K(CA)3. ion channel modulator has shown promising efficacy in multiple preclinical models of inflammation and fibrosis, including potential best-in-class data for the rare disease idiopathic pulmonary fibrosis (IPF), a market estimated at more than USD $2B (SEK 19 billion)."

Licensing / partnership • New P1 trial • Preclinical • Idiopathic Pulmonary Fibrosis

Saniona voluntarily breaks phase 2b study with Tesomet, takes staff reduction of 30 percent (Realtid) - "The company also continues to invest in its platform for drug discovery in ion channels, including SAN903 which is expected to begin phase 1 studies in the second half of 2022 and discovery research, which in 2022 is expected to advance a new ion channel modulator to the preclinical pipeline."

New P1 trial • Preclinical • Idiopathic Pulmonary Fibrosis

Saniona publishes its interim report for the second quarter of 2021 (GlobeNewswire) - "Saniona presented preclinical data from its ion channel program SAN903 in a model of idiopathic pulmonary fibrosis at the American Society of Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting. SAN903 is expected to enter Phase 1 in the second half of 2022."

New P1 trial • Preclinical • Idiopathic Pulmonary Fibrosis • Respiratory Diseases

Saniona to Present Preclinical Data on SAN903 at the ASPET Annual Meeting at Experimental Biology 2021 (GlobeNewswire) - "Saniona...announced that its research team will present preclinical data on SAN903 in a model of idiopathic pulmonary fibrosis at the American Society of Pharmacology and Experimental Therapeutics (ASPET) Annual Meeting at Experimental Biology (EB) 2021, which is being held virtually between April 27 and 30, 2021....Expects to initiate Phase 1 clinical trials in the first half of 2022....Saniona also plans to share its SAN903 preclinical data in additional scientific and investor forums in the future."

New P1 trial • Preclinical • Idiopathic Pulmonary Fibrosis

Saniona publishes its interim report for the second quarter 2019 (GlobeNewswire, Saniona AB) - "Saniona selected a development candidate, SAN903, in the IK program. Based on work done to date, Saniona has elected to focus SAN903 initially on the treatment of Crohn’s disease and colitis. The program may potentially be ready for Phase 1 clinical studies within 18 months. In July Saniona received the gross proceeds of SEK 66.5 million from the Rights Issue. The net proceeds after transaction costs is SEK 53.7 million. The number of shares outstanding after the Rights Issue is 27,763,347."

Clinical • Commercial • New trial

Newly added product (GlobeNewswire) - Preclinical, Inflammatory Bowel Disease

Pipeline update

Saniona selects highly promising preclinical candidate with broad potential in autoimmune disorders (GlobeNewswire, Saniona AB) - "Saniona...announces that it has selected a new development candidate, SAN903, for preclinical development, which can enter clinical Phase 1 in only 18 months. Based on work done to date, Saniona has elected to focus SAN903 initially on the treatment of Crohn’s disease and colitis....Saniona is concurrently working with its development partners to initiate Phase 1 clinical trials early 2021."

New trial • Preclinical